< Brochure Homepage | Faculty Index | Pathology Homepage

Email kking@jhmi.edu
Phone (410) 955-6583

Karen E. King, M.D.

Primary Appointment in Pathology
Secondary Appointment in Oncology
Co Director, Pathology Residency Program
Director, Transfusion Medicine Fellowship Program

My research is focused in two areas: 1) the evaluation, treatment and prevention of adverse events due to transfusion, and 2) novel indications for apheresis. My interests involve the complications related to transfusion including alloimmunization, febrile non-hemolytic transfusion reactions, allergic transfusion reactions and septic transfusion reactions. I am particularly interested in the role of transfusion and transfusion-related complications in the care of patients with sickle cell disease, especially issues due to multiple transfusions and alloimmunization, including delayed hemolytic transfusion reactions and the phenomenon of bystander hemolysis. In the area of apheresis, I have studied the role of apheresis in novel clinical settings including ABO and HLA incompatible kidney transplantation, HLA incompatible progenitor cell transplantation and neurologic diseases such as Stiff Person Syndrome. In the Hemapheresis and Transfusion Support (HATS) service, our resources include apheresis technology and staff skilled in performing therapeutic and donor apheresis. Our platelet coordinators manage platelet transfusion therapy for multitransfused, refractory patients. The translational aspects of this service facilitate close interactions with research and clinical investigators in many fields. I am also involved in clinical trials related to transfusion medicine and novel apheresis technologies.


Transfusion-related Adverse Events:
King KE, Shirey RS, Lankiewicz MW, Young-Ramsaran J, Ness PM. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells. Transfusion 1997;37:376-381. PMID: 9111274

Ness PM, Shirey RS, Weinstein MH, King KE. An animal model for delayed hemolytic transfusion reactions. Transfusion Medicine Reviews 2001;15:305-317. PMID: 11668437

Shirey RS, Boyd JA, Parwani AV, Tanz WS, Ness PM, King KE. Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management. Transfusion 2002;42:1435-1441. PMID: 12421216

King KE, Shirey RS, Thoman SK, Bensen-Kennedy D, Tanz WS, Ness PM. Universal leukoreduction decreases the incidence of febrile non-hemolytic transfusion reactions to RBCs. Transfusion 2004;44:25-29. PMID: 14692963

Tobian AAR, Fuller AK, Uglik K, Tisch DJ, Borge PD, Benjamin RJ, Ness PM, King KE. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment. Transfusion 2014;54:1523-1529. PMID:24251374.

Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into crossmatch positive recipients. Transplantation 2000;70:887-95. PMID: 11014642

Montgomery RA, Locke JE, King KE, Segev DL, Warren DS, Kraus ES, Cooper M, Simpkins CE, Singer AL, Stewart ZA, Melancon JK, Ratner L. Zachary AA, Haas M. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009;87:1246-1255. PMID: 19384174

Montgomery RA, Segev DL, Lonze BE, Haas M, King KE, Kraus ES, Locke JE, Warren DS, Cooper M, Simpkins CE, Dagher NN, Singer AL, Samaniego-Picota MD, Ratner LE, Kucirka LM, Leffell MS, Zachary AA. Desensitization in HLA-incompatible kidney recipients and survival. New England Journal of Medicine 2011;365:318-326. PMID: 21793744

Gladstone DE, Zachary AA, Fuchs EJ, Luznick L, Kasamon YL, King KE, Brodsky R, Jones RJ, Leffell MS. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biology of Blood and Marrow Transplantation 2013;19:647-652. PMID:23353119

Pagano MB, Murinson BB, Tobian AAR, King KE. Efficacy of therapeutic plasma exchange for treatment of stiff person syndrome. Transfusion 2014;54:1851-1856. PMID: 24527774.


Copyright © 2017 Johns Hopkins University. All Rights Reserved